Literature DB >> 2777511

Regulation of the metastasis of murine ocular melanoma by natural killer cells.

R Harning1, G C Koo, J Szalay.   

Abstract

In the current study we examine parameters affecting the metastasis of ocular tumors of in vivo derived B16F10 melanoma. In C57BL/6J beige (bg/bg) mice, with low NK activity, metastasis to the lungs was increased and survival time decreased. In C57BL/6J normal (+/+) mice treatment with PK136, a highly specific monoclonal anti-NK antibody (Ab), caused a depletion of NK cytotoxic activity, as demonstrated using a standard 51Cr release assay. In animals bearing ocular tumors, treatment with PK136 Ab resulted in significantly increased pulmonary metastasis and an altered pattern of metastasis. The effect of combined treatment protocols using LS2616 (linomide) and cyclophosphamide (Cy) was examined in enucleated and unenucleated animals. Treatment with LS2616 and Cy resulted in a significant decrease in mean pulmonary metastases (MPM), a decreased frequency of metastasis to the submandibular lymph nodes and an increase in mean survival time. In enucleated mice this combined treatment protocol resulted in apparent cures, the lowest MPM and the longest survival time observed. When tumor-bearing mice were treated with either silica, carrageenan or sublethal gamma irradiation, no effect on metastasis or survival was observed. This study demonstrates the importance of the NK cell as a primary effector cell for the control of metastasis from in vivo derived ocular B16F10 melanoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777511

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

3.  Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.

Authors:  Tehila Azoulay; Ilana Slouzky; Michal Karmona; Margarita Filatov; Michal Hayun; Yishai Ofran; Galit Sarig; Shimrit Ringelstein-Harlev
Journal:  Cancer Immunol Immunother       Date:  2022-09-01       Impact factor: 6.630

4.  The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo.

Authors:  P Borgström; I P Torres Filho; P Vajkoczy; K Strandgården; J Polaçek; B Hartley-Asp
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.

Authors:  J Kan-Mitchell; P E Liggett; W Harel; L Steinman; T Nitta; J R Oksenberg; M R Posner; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.

Authors:  M Ziche; S Donnini; L Morbidelli; A Parenti; G Gasparini; F Ledda
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

7.  A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

Authors:  M J Mackean; D Kerr; M Lesko; A Svedberg; F Hansson; D Jodrell; J Cassidy
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

8.  Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy.

Authors:  Christine V Ichim
Journal:  J Transl Med       Date:  2005-02-08       Impact factor: 5.531

9.  Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells.

Authors:  Kawaljit Kaur; Meng-Wei Ko; Nick Ohanian; Jessica Cook; Anahid Jewett
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

10.  Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.

Authors:  F Vaz; M R Silva; J L Ascensao
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.